Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanna Jacobus

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|September 9, 2011
The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressivenessTong Sun, William K Oh, Susanna Jacobus, et al.
Cancer|December 19, 2007
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxelRobert W Ross, Tomasz M Beer, Susanna Jacobus, et al.
BJU International|January 11, 2008
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancerMari Nakabayashi, Oliver Sartor, Susanna Jacobus, et al.
Clinical Genitourinary Cancer|September 22, 2016
Radium-223 Use in Clinical Practice and Variables Associated With Completion of TherapyRana R McKay, Susanna Jacobus, Matthew Fiorillo, et al.
The Lancet. Oncology|October 27, 2009
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialS Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, et al.
Journal of Medical Internet Research|May 3, 2019
Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized TrialRana McKay, Hannah Mills, Lillian Werner, et al.
Cancer|September 24, 2010
Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patientsWilliam K Oh, Roberto Vargas, Susanna Jacobus, et al.
Blood Cancer Journal|July 8, 2018
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trialsSikander Ailawadhi, Susanna Jacobus, Rachael Sexton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysisHajime Uno, Brian Claggett, Lu Tian, et al.
Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Cancer Prevention Research (Philadelphia, Pa.)|September 9, 2011
The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressivenessTong Sun, William K Oh, Susanna Jacobus, et al.
Cancer|December 19, 2007
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxelRobert W Ross, Tomasz M Beer, Susanna Jacobus, et al.
BJU International|January 11, 2008
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancerMari Nakabayashi, Oliver Sartor, Susanna Jacobus, et al.
Clinical Genitourinary Cancer|September 22, 2016
Radium-223 Use in Clinical Practice and Variables Associated With Completion of TherapyRana R McKay, Susanna Jacobus, Matthew Fiorillo, et al.
The Lancet. Oncology|October 27, 2009
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialS Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, et al.
Journal of Medical Internet Research|May 3, 2019
Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized TrialRana McKay, Hannah Mills, Lillian Werner, et al.
Cancer|September 24, 2010
Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patientsWilliam K Oh, Roberto Vargas, Susanna Jacobus, et al.
Blood Cancer Journal|July 8, 2018
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trialsSikander Ailawadhi, Susanna Jacobus, Rachael Sexton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysisHajime Uno, Brian Claggett, Lu Tian, et al.
Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Pageof 3